Efficacy of contrast-enhanced US versus CT or MRI for the therapeutic control of percutaneous radiofrequency ablation in the case of hepatic malignancies

Ultraschall in der Medizin

Volumn 32, Issue 2, 2011, Pages 148-153

  Frieser, M ^a   Kiesel, J ^a   Lindner, A ^a   Bernatik, T ^a   Haensler, J M ^a   Janka, R ^a   Hahn, E G ^a   Strobel, D ^a  

^a NOZ   (Germany)

Author keywords

abdomen; ablation procedures; contrast agents

Indexed keywords

CONTRAST AGENT BR1; CONTRAST MEDIUM; DIAGNOSTIC AGENT; PHOSPHOLIPID; SULFUR HEXAFLUORIDE;

ADULT; AGED; ARTICLE; CATHETER ABLATION; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMAGE PROCESSING; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MINIMALLY INVASIVE SURGERY; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSTOPERATIVE COMPLICATION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CONTRAST MEDIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOLIPIDS; POSTOPERATIVE COMPLICATIONS; SENSITIVITY AND SPECIFICITY; SULFUR HEXAFLUORIDE; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ULTRASONOGRAPHY; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 79953799349     PISSN: 01724614     EISSN: 14388782     Source Type: Journal    
DOI: 10.1055/s-0029-1245934     Document Type: Article

References (24)

1. Spangenberg H C., Thimme R, Blum H E. Evolving therapies in the treatment of hepatocellular carcinoma. Biologics 2008 2 453-462
2. El-Serag H B., Marrero J A., Rudolph L et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008 134 1752-1763 (Pubitemid 351615415)
3. Lau W Y., Lai E C. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008 7 237-257 (Pubitemid 351895383)
4. Abdalla E K., Vauthey J N., Ellis L M. et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004 239 818-825; discussion 825 - 827
5. Abdel-Misih S R., Schmidt C R., Bloomston P M. Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases. World J Surg Oncol 2009 7 72
6. Guan Y S., Sun L, Zhou X P. et al. Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up. World J Gastroenterol 2004 10 (24) 3543-3548 (Pubitemid 39619265)
7. Goldberg S N., Grassi C J., Cardella J F. et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 2005 235 728-739 Epub 2005 Apr 21. Review (Pubitemid 40695866)
8. Couinaud C. Segmental and lobar left hepatectomies, studies on anatomical conditions. J Chir 1952 68 697-715
9. EFSUMB Study Group. Guidelines for the use of contrast agents in ultrasound. Ultraschall in Med 2004 25 249-256
10. Claudon M, Cosgrove D, Albrecht T et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall in Med 2008 29 28-44 (Pubitemid 351294171)
11. Strobel D, Seitz K, Blank W et al. Contrast-enhanced ultrasound for the characterization of focal liver lesions - diagnostic accuracy in clinical practice (DEGUM multicenter trial). Ultraschall in Med 2008 29 499-505
12. Strobel D, Seitz K, Blank W et al. Tumor-specific vascularization pattern of liver metastasis, hepatocellular carcinoma, hemangioma and focal nodular hyperplasia in the differential diagnosis of 1,349 liver lesions in contrast-enhanced ultrasound (CEUS). Ultraschall in Med 2009 30 376-382 Epub 2009 Aug 17
13. Seitz K, Strobel D, Bernatik T et al. Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions - prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreilndertreffen 2008, Davos. Ultraschall in Med 2009 30 383-389 Epub 2009 Aug 17
14. Choi D, Lim H K., Lee W J. et al. Radiofrequency ablation of liver cancer: early evaluation of therapeutic response with contrast-enhanced ultrasonography. Korean J Radiol 2004 5 185-198 (Pubitemid 39430480)
15. Lu M D., Yu X L., Li A H. et al. Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multi-center study in China. Ultrasound Med Biol 2007 33 (11) 1736-1749 Epub 2007 Jul 16
16. Shimizu M, Iijima H, Horibe T et al. Usefulness of contrast-enhanced ultrasonography with a new contrast mode, Agent Detection Imaging, in evaluating therapeutic response in hepatocellular carcinoma treated with radio-frequency ablation therapy. Hepatol Res 2004 29 235-242 (Pubitemid 39060778)
17. Imai Y, Okamoto N, Tateiwa N et al. Assessment of treatment efficacy in radiofrequency ablation for hepatocellular carcinoma: Comparison between multiplanar reconstruction by multi-detector row CT and contrast-enhanced ultrasonography by Truagent detection mode. Hepatol Res 2006 35 69-75. Epub 2006 Mar 10
18. Kim C K., Choi D, Lim H K. et al. Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: utility of contrast-enhanced agent detection imaging. Eur J Radiol 2005 56 66-73 (Pubitemid 41316489)
19. Solbiati L, Ierace T, Tonolini M et al. Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound. Eur J Radiol 2004 51 S19-S23 (Pubitemid 38845009)
20. Meloni M F., Livraghi T, Filice C et al. Radiofrequency ablation of liver tumors: the role of microbubble ultrasound contrast agents. Ultrasound Q 2006 22 41-47 (Pubitemid 44510226)
21. Ricci P, Cantisani V, Drudi F et al. Is contrast-enhanced US alternative to spiral CT in the assessment of treatment outcome of radiofrequency ablation in hepatocellular carcinoma? Ultraschall in Med 2009 30 252-258 Epub 2009 Mar 11
22. Vogt F M., Antoch G, Veit P et al. Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT. J Nucl Med 2007 48 1836-1844. Epub 2007 Oct 17 (Pubitemid 350099330)
23. Schraml C, Clasen S, Schwenzer N F. et al. Diagnostic performance of contrast-enhanced computed tomography in the immediate assessment of radiofrequency ablation success in colorectal liver metastases. Abdom Imaging 2008 33 643-651
24. Kim S K., Lim H K., Kim Y H. et al. Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings. Radiographics 2003 23 107-121 (Pubitemid 37421439)